Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
Hosted on MSN42m
Arcturus Therapeutics appoints Moncef Slaoui as chair designate
Arcturus Therapeutics (ARCT) announced the appointment of Moncef Slaoui as chair designate. Slaoui has been serving on the company’s board of ...
Arcturus: Downgrading As mRNA Promise Meets Market Reality
Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...
Ed Arce’s Buy Rating on Arcturus Therapeutics Driven by Strategic Advancements and Strong Market Positioning
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a ...
Demystifying Arcturus Therapeutics: Insights From 5 Analyst Reviews
In the assessment of 12-month price targets, analysts unveil insights for Arcturus Therapeutics, presenting an average target ...
Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
SEC Oil Fraud Case Gets Nod for Over $10 Million in Remedies
Oil and gas companies Arcturus Corp. and Aschere Energy LLC, along with founder Leon Ali Parvizian, must pay more than $10 ...
Arcturus Therapeutics initiated with a Buy at BTIG
BTIG initiated coverage of Arcturus Therapeutics (ARCT) with a Buy rating and $41 price target Arcturus is a commercial-stage biotechnology ...
Arcturus Therapeutics (NASDAQ:ARCT) Now Covered by Analysts at BTIG Research
BTIG Research began coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) in a research report issued on Tuesday, MarketBeat reports. The brokerage set a “buy” rating and a ...
Leerink Partnrs Has Bullish Outlook for ARCT FY2024 Earnings
Equities research analysts at Leerink Partnrs upped their FY2024 EPS estimates for shares of Arcturus Therapeutics in a note ...
Arcturus Therapeutics names Moncef Slaoui as Chair Designate
Holdings Inc. (NASDAQ: ARCT), a company specializing in mRNA medicines for infectious diseases and rare disorders, has appointed Dr. Moncef Slaoui as its Chair Designate. Dr. Slaoui, a notable figure ...